According to Dongxing Medical, the company signed a contract with Academician Deng Zixin's team from Shanghai Jiaotong University to promote the industrialization of research and development of recombinant humanized collagen. Relying on Deng Zixin's team's technology and platform, Dongxing Medical has completed research and development of recombinant humanized type III short-chain and recombinant humanized type III full-length single-chain strains and built a 10-ton fermentation production line. It is expected that these two strains will be officially put into production in January 2027.

According to Dongxing Medical, the company signed a contract with Academician Deng Zixin's team from Shanghai Jiaotong University to promote the industrialization of research and development of recombinant humanized collagen. Relying on Deng Zixin's team's technology and platform, Dongxing Medical has completed research and development of recombinant humanized type III short-chain and recombinant humanized type III full-length single-chain strains and built a 10-ton fermentation production line. It is expected that these two strains will be officially put into production in January 2027.